SEARCH

SEARCH BY CITATION

References

  • 1
    Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. Aliment Pharmacol Ther 2003; 17: 64350.
  • 2
    Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005; 100: 117484.
    Direct Link:
  • 3
    Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003; 163: 92935.
  • 4
    Zacker C, Chawla A, Wang S, Albers L. Absenteeism among employees with irritable bowel syndrome. Manag Care Interface 2004; 17: 2832.
  • 5
    Smith GD, Steinke DT, Kinnear M, Penny KI, Pathmanathan N, Penman ID. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract 2004; 54: 5037.
  • 6
    Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002; 20: 45562.
  • 7
    Brandt LJ, Bjorkman D, Fennerty B, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97 (11 Suppl.): S726.
  • 8
    Icks A, Haastert B, Enck P, Rathmann W, Giani G. Prevalence of functional bowel disorders and related health care seeking: a population-based study. Z Gastroenterol 2002; 40: 17783.
  • 9
    Kong SC, Hurlstone DP, Pocock CY, et al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005; 39: 13841.
  • 10
    Müller-Lissner SA, Pirk O. Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol 2002; 14: 132529.
  • 11
    Dapoigny M, Bellanger J, Bonaz B, et al. Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol 2004; 16: 9951001.
  • 12
    Goettsch WG, Van Den Boom G, Breekveldt-Postma NS, Smout AJPM, Herings RM. Treatment patterns and health care costs of mebeverine-treated IBS patients: a case–control study. Pharmacoepidemiol Drug Saf 2004; 13: 80310.
  • 13
    ACG. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97 (11 Suppl.): S15.
  • 14
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. 2): II43II47.
  • 15
    Veldhuyzen van Zanten S, Talley N, Bytzer P, Klein P, Whorwell P, Zinsmeister A. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45 (Suppl. 2): 6977.
  • 16
    CPMP. Points to Consider on the Evaluation of Medicinal Products for the Treatment of Irritable Bowel Syndrome (CPMP/EWP/785/97). London: CPMP, 2003.
  • 17
    Wheatley D. Irritable colon syndrome treated with an anti-spasmodic drug. Practitioner 1976; 217: 27680.
  • 18
    Page JG, Dirnberger MS. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981; 3: 1536.
  • 19
    Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. BMJ 1979; 1: 3768.
  • 20
    Kruis W, Weinzierl M, Scussler P. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion 1986; 34: 196201.
  • 21
    Tudor GJ. A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome. Br J Clin Pract 1986; 40: 2768.
  • 22
    Chapman ND, Grillage MG, Mazumder R, Atkinson SN. A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomized, parallel group study. Br J Clin Pract 1990; 44: 4616.
  • 23
    Awad R, Dibildox M, Ortiz F. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. Acta Gastroenterol Latinoam 1995; 25: 13744.
  • 24
    Baldi F, Longanesi A, Blasi A, et al. Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. Ital J Gastroenterol Hepatol 1991; 23 (8 Suppl. 1): 603.
  • 25
    Villagrasa M, Boix J, Humbert P, Quer JC. Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome. Ital J Gastroenterol 1991; 23 (8 Suppl. 1): 6770.
  • 26
    Battaglia G, Morselli-Labate AM, Camarri E, et al. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 1998; 12: 100310.
  • 27
    Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2002; 14: 13318.
  • 28
    Ferrari A, Cavallero M, Spandre M, Gemme C, Rossini FP. Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome. Clin Ther 1986; 8: 3208.
  • 29
    Piai G, Visconti M, Imbimbo BP, Minieri M, Sollazzo R, Mazzaca G. Long-term treatment of irritable bowel syndrome with cimetropium bromide, a new antimuscarinic compound. Curr Ther Res 1987; 41: 96777.
  • 30
    Centonze V, Imbimbo BP, Campanozzi F, Attolini E, Daniotti S, Albano O. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol 1988; 83: 12626.
  • 31
    Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Long-term treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut 1990; 31: 3558.
  • 32
    Fielding JF. Double blind trial of trimebutine in the irritable bowel syndrome. Ir Med J 1980; 73: 3779.
  • 33
    Luttecke K. A three-part controlled trial of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin 1980; 6: 43743.
  • 34
    Ghidini O, Saponati G, Intrieri L. Single drug treatment for irritable colon: rociverine versus trimebutine maleate. Curr Ther Res 1986; 39: 54148.
  • 35
    Schaffstein W, Panijel M, Lüttecke K. Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Curr Ther Res 1990; 47: 13645.
  • 36
    Gilvarry J, Kenny A, Fielding JF. The non-effect of pirenzepine in dietary resistant irritable bowel syndrome. Ir J Med Sci 1989; 158: 262.
  • 37
    Piai G, Visconti M, Minieri M, Sollazzo R, Mazzaca G, Imbimbo BP. Treatment of irritable bowel syndrome. Clin Trials J 1986; 23: 610.
  • 38
    Valenzuela J, Alvarado J, Cohen H, et al. Latin-American consensus document on irritable bowel syndrome. Gastroenterol Hepatol 2004; 27: 32543.
  • 39
    Quartero A, Meineche-Schmidt V, Muris J, Rubin G, De Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; CD003460.
  • 40
    Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 125369.
  • 41
    Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 499510.
  • 42
    Soltoft J, Krag B, Gudmand-Hoyer E, Kristensen E, Wulff HR. A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. Lancet North Am Ed 1976; 11: 2702.
  • 43
    Manning AP, Heaton KW, Harvey RF. Wheat fibre and irritable bowel syndrome. A controlled trial. Lancet North Am Ed 1977; 2: 4178.
  • 44
    Longstreth GF, Fox DD, Youkeles L, Forsythe AB, Wolochow DA. Psyllium therapy in the irritable bowel syndrome. Ann Intern Med 1981; 95: 536.
  • 45
    Golechha AC, Chadda VS, Chadda S, Sharma SK, Mishra SN. Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double-blind crossover study). J Assoc Physicians India 1982; 30: 3535.
  • 46
    Arthurs Y, Fielding JF. Double blind trial of ispaghula/poloxamer in the Irritable Bowel Syndrome. Ir Med J 1983; 76: 253.
  • 47
    Arffmann S, Andersen JR, Hegnhøj J, Schaffalitzky de Muckadell OB, Mogensen NB, Krag E. The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind, cross-over study. Scand J Gastroenterol 1985; 20: 2958.
  • 48
    Lucey MR, Clark ML, Lowndes J, Dawson AM. Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. Gut 1987; 28: 2215.
  • 49
    Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut 1987; 28: 15103.
  • 50
    Cook IJ, Irvine EJ, Campbell D, Shannon S, Reddy SN, Collins SM. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, cross over study. Gastroenterology 1990; 98: 6672.
  • 51
    Jalihal A, Kurian G. Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction. J Gastroenterol Hepatol 1990; 5: 50713.
  • 52
    Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 8792.
  • 53
    Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 5114.
  • 54
    Fowlie S, Eastwood MA, Prescott R. Irritable bowel syndrome: assessment of psychological disturbance and its influence on the response to fibre supplementation. J Psychosom Res 1992; 36: 17580.
  • 55
    Fielding JF. Domperidone treatment in the irritable bowel syndrome. Digestion 1982; 23: 1257.
  • 56
    Aller R, De Luis DA, Izaola O, et al. Effects of a high-fiber diet on symptoms of irritable bowel syndrome: a randomized clinical trial. Nutrition 2004; 20: 7357.
  • 57
    Rees G, Davies J, Thompson R. Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome. J R Soc Health 2005; 125: 304.
  • 58
    Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1984; 29: 23947.
  • 59
    Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol 1987; 130: 814.
  • 60
    Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 4638.
  • 61
    Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome – a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987; 130: 7780.
  • 62
    Taneja I, Deepak KK, Poojary G, Acharya IN, Pandey RM, Sharma MP. Yogic versus conventional treatment in diarrhoea-predominant irritable bowel syndrome: a randomized control study. Appl Psychophysiol Biofeed 2004; 29: 1933.
  • 63
    Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996; 91: 157985.
  • 64
    Cann PA, Read NW, Holdsworth CD. Oral domperidone: double blind comparison with placebo in irritable bowel syndrome. Gut 1983; 24: 113540.
  • 65
    Milo R. Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome. Curr Med Res Opin 1980; 6: 57784.
  • 66
    Heefner JD, Wilder RM, Wilson JD. Irritable colon and depression. Psychosomatics 1978; 19: 5407.
  • 67
    Steinhart MJ, Wong PY, Zarr ML. Therapeutic usefulness of amitriptyline in spastic colon syndrome. Int J Psychiatry Med 1981; 11: 4557.
  • 68
    Myren J, Groth H, Larssen SE, Larsen S. The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study. Scand J Gastroenterol 1982; 17: 8715.
  • 69
    Myren J, Lovland B, Larssen SE, Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984; 19: 83543.
  • 70
    Greenbaum DS, Mayle JE, Vanegeren LE, et al. The effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987; 32: 25766.
  • 71
    Vij JG, Jiloha RG, Kumar N, Madhu SV, Malika V, Anand BS. Effect of antidepressant drug (doxepin) on irritable bowel syndrome. Indian J Psychiatry 1991; 33: 2436.
  • 72
    Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998; 13: 73841.
  • 73
    Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124: 30317.
  • 74
    Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004; 99: 91420.
    Direct Link:
  • 75
    Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 21928.
  • 76
    Whorwell PJ, Krumholz S, Müller-Lissner SM, Schmitt C, Dunger-Baldauf C, Rueegg PC. Tegaserod has a favorable safety and tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome (IBS). Gastroenterology 2000; 118: A5529.
  • 77
    Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 165566.
  • 78
    Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 187788.
  • 79
    Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 6716.
  • 80
    Hämling J, Bang CJ, Tarpila S, Stewart W, Rueegg P. Titration regimen indicates partial 5-HT4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (C-IBS). Digestion 1998; 59 (Suppl. 3): 735: ExhB5329.
  • 81
    Lefkowitz MP, Shi Y, Schmitt C, Krumholz S, Tanghe J. The 5-HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS). Am J Gastroenterol 1999; 94: 266.
  • 82
    Lefkowitz MP, Rueegg P, Shi Y, Dunger-Baldauf C. Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF 919. Gastroenterology 1999; 116: A1027.
  • 83
    Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004; 39: 11926.
  • 84
    Tack J, Müller-Lissner SA, Bytzer P, et al. Tegaserod provides rapid and sustained relief of overall IBS symptoms and abdominal discomfort/pain when used as repeated treatment in women with IBS-C. Gut 2004; 53 (Suppl. VI): A69.
  • 85
    Fidelholtz J, Smith W, Rawls J, et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhoea symptoms. Am J Gastroenterol 2002; 97: 117681.
    Direct Link:
  • 86
    Schoenfeld P, Chey WD, Drossman D, et al. Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Gastroenterology 2002; 122: A46S [abstract].
  • 87
    Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 35460.
  • 88
    Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003; 67: 829.
  • 89
    Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000; 14: 77582.
  • 90
    Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 84955.
  • 91
    Mayer EA, Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin Pharmacother 2003; 4: 208998.
  • 92
    Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther 1996; 10: 5959.
  • 93
    Goldberg PA, Kamm MA, Setti-Carraro P, Van Der Sijp J, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996; 57: 47883.
  • 94
    Steadman CJ, Talley NJ, Phillips SF, Zinsmeister AR. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhoea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992; 67: 7328.
  • 95
    Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel function patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 114959.
  • 96
    Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 141927.
  • 97
    Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet North Am Ed 2000; 355: 103540.
  • 98
    Lembo T, Wright RA, Bagby B et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhoea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 266270.
    Direct Link:
  • 99
    Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 2334.
  • 100
    Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhoea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 173340.
  • 101
    Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhoea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99: 2195203.
    Direct Link:
  • 102
    Lembo AJ, Olden KW, Ameen VZ, et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhoea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2004; 2: 67582.
  • 103
    Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 7986.
  • 104
    Bradette M, Moennikes H, Carter F, Krause G, Caras S, Steinborn C. Cilansetron in irritable bowel syndrome with diarrhoea predominance (IBS-D): efficacy and safety in a 6 month global study. Gastroenterology 2004; 126 (Suppl. 2): A42 [abstract].
  • 105
    Coremans G, Clouse RE, Carter F, et al. Cilansetron, a novel 5-HT3 antagonist demonstrated efficacy in males with irritable bowel syndrome with diarrhoea-predominance (IBS-D). Gastroenterology 2004; 126 (4 Suppl. 2): A-643.
  • 106
    Van Outryve M, Milo R, Toussaint J, Van Eegham P. ‘Prokinetic’ treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991; 13: 4957.
  • 107
    Schütze K, Brandstatter G, Dragosics B, Judmaier G, Hentschel E. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 38794.
  • 108
    Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Hovde O, Trondstad R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998; 33: 12831.
  • 109
    Noor N, Small PK, Loudon MA, Hau C, Campbell FC. Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome. Scand J Gastroenterol 1998; 33: 60511.
  • 110
    Ziegenhagen DJ, Kruis W. Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo. J Gastroenterol Hepatol 2004; 19: 7449.
  • 111
    Henderson JC, Palmer RMJ, Meyers NL, Spiller RC. A phase IIb clinical study of renzapride in mixed-symptom (alternating) irritable bowel syndrome. Gastroenterology 2004; 126 (Suppl. 2): A-915.
  • 112
    Meyers N, Palmer R, George A. Efficacy and safety of renzapride in patients with constipation-predominant IBS: a Phase IIb study in the UK primary healthcare setting. Gastroenterology 2004; 126 (Suppl. 2): A-640.
  • 113
    Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004; 2: 895904.
  • 114
    Lea R, Whorwell PJ. Benefit-risk assessment of tegaserod in irritable bowel syndrome. Drug Saf 2004; 27: 22942.
  • 115
    Barbey JT, Lazzara R, Zipes DP. Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 2002; 7: 6576.
  • 116
    Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122: 114056.
  • 117
    Svedlund J, Sjodin I, Ottosson JO, Dotevall G. Controlled study of psychotherapy in irritable bowel syndrome. Lancet 1983; 2: 58992.
  • 118
    Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984; 2: 123234.
  • 119
    Bennett P, Wilkinson S. Comparison of psychological and medical treatment of the irritable bowel syndrome. Br J Clin Psychol 1985; 24: 2156.
  • 120
    Harvey RF, Hinton RA, Gunary RM, Barry RE. Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. Lancet 1989; 1: 4245.
  • 121
    Lynch PM, Zamble EA. Controlled behavioural treatment study of irritable bowel syndrome. Behav Ther 1989; 20: 50923.
  • 122
    Corney RH, Stanton R, Newell R, Clare A, Fairclough P. Behavioural psychotherapy in the treatment of irritable bowel syndrome. J Psychosom Res 1991; 35: 4619.
  • 123
    Rumsey N. Group stress management programmes vs pharmacological treatment in the treatment of irritable bowel syndrome. In: HeatonKW, CreedF, GoetingNLM, eds. Towards Confident Management of Irritable Bowel Syndrome: Current Approaches. London: Duphar Medical Relations, 1991: 335.
  • 124
    Shaw G, Srivastava ED, Sadlier M, Swann P, James JY, Rhodes J. Stress management for irritable bowel syndrome: a controlled trial. Digestion 1991; 50: 3642.
  • 125
    Blanchard EB, Schwarz SP, Suls JM, et al. Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome. Behav Res Ther 1992; 30: 17589.
  • 126
    Blanchard EB, Greene B, Scharff L, Schwarz-McMorris SP. Relaxation training as a treatment for irritable bowel syndrome. Biofeedback Self Regul 1993; 18: 12532.
  • 127
    Guthrie E, Creed F, Dawson D, Tomenson B. A randomised controlled trial of psychotherapy in patients with refractory irritable bowel syndrome. Br J Psychiatry 1993; 163: 31521.
  • 128
    Greene B, Blanchard EB. Cognitive therapy for irritable bowel syndrome. J Consult Clin Psychol 1994; 62: 57682.
  • 129
    Payne A, Blanchard E. A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. J Consult Clin Psychol 1995; 63: 77986.
  • 130
    Galovski TE, Blanchard EB. The treatment of irritable bowel syndrome with hypnotherapy. Appl Psychophysiol Biofeedback 1998; 23: 21932.
  • 131
    Heymann-Monnikes I, Arnold R, Florin I, Herda C, Melfsen S, Monnikes H. The combination of medical treatment plus multicomponent behavioural therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 98194.
    Direct Link:
  • 132
    Vollmer A, Blanchard EB. Controlled comparison of individual versus group cognitive therapy for irritable bowel syndrome. Behav Ther 1998; 29: 1933.
  • 133
    Tkachuk GA, Graff LA, Martin GL, Bernstein CN. Randomized controlled trial of cognitive-behavioural group therapy for irritable bowel syndrome in a medical setting. J Clin Psychol Medical Settings 2003; 10: 5769.
  • 134
    Simren M, Ringstrom G, Bjornsson ES, Abrahamsson H. Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome. Psychosom Med 2004; 66: 2338.
  • 135
    Heitkemper MM, Jarrett ME, Levy RL, et al. Self-management for women with irritable bowel syndrome. Clin Gastroenterol Hepatol 2004; 2: 58596.
  • 136
    Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 220918.
    Direct Link:
  • 137
    Forbes A, MacAuley S, Chiotakakou-Faliakou E. Hypnotherapy and therapeutic audiotape. Int J Colorectal Dis 2000; 15: 32834.
  • 138
    Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA. Naloxone treatment for irritable bowel syndrome – a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002; 16: 164954.
  • 139
    Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist, fedotozine, versus placebo in treatment of irritable bowel syndrome. A multicenter dose–response study. Dig Dis Sci 1995; 40: 22449.
  • 140
    Camilleri M, Kim DY, McKinzie S, et al. A randomized, controlled exploratory study of clonidine in diarrhoea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003; 1: 11121.
  • 141
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 4129.
  • 142
    Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997; 32: 7658.
  • 143
    Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998; 280: 15859.
  • 144
    Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 11437.
  • 145
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Aliment Pharmacol Ther 2005; 21: 43544.
  • 146
    Lembo A. Irritable bowel syndrome medications side effects survey. J Clin Gastroenterol 2004; 38: 77681.
  • 147
    Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 56980.